Opioid tolerance and urine drug testing among initiates of extended-release or long-acting opioids in Food and Drug Administration's Sentinel System
DOI:
https://doi.org/10.5055/jom.2017.0407Keywords:
opioid analgesics, opioid tolerance, urine drug testingAbstract
Objective: A risk evaluation and mitigation strategy for extended-release and long-acting (ER/LA) opioid analgesics was approved by the Food and Drug Administration in 2012. Our objective was to assess frequency of opioid tolerance and urine drug testing for individuals initiating ER/LA opioid analgesics.
Design: Retrospective cohort study.
Setting: Sentinel, a distributed database with electronic healthcare data on >190 million predominantly commercially insured members.
Patients, participants: Members under age 65 initiating ER/LA opioid analgesics between January 2009 and December 2013.
Main outcome measure(s): We examined the proportion of opioid-tolerantonly ER/LA opioid analgesic initiates meeting tolerance criteria: receipt of ≥30 mg oxycodone equivalents per day in 7 days prior to the first opioid-tolerant-only dispensing. We separately examined the proportion of new users of extended-release oxycodone (ERO) and other ER/LA opioid analgesics with a claim for a urine drug test in the 30 days prior to, and separately for the 183 days after, dispensing.
Results: We identified 79,824 ERO, 7,343 extended-release hydromorphone, and 91,778 transdermal fentanyl opioid-tolerant-only episodes. Tolerance criteria were met in 64 percent of ERO, 64 percent of extended-release hydromorphone and 40 percent of transdermal fentanyl episodes. We identified 210,581 incident ERO and 311,660 other ER/LA opioid analgesic episodes. Use of urine drug testing for ERO compared with other ER/LA opioid analgesics was: 4 percent vs 14 percent respectively in the 30 days prior to initiation and 9 percent vs 23 percent respectively in the 183 days following initiation.
Conclusions: These results suggest potential areas for improving appropriate ER/LA opioid analgesic prescribing practices.
References
Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. 2015. Report No.: HHS Publication No. SMA 15-4927, NSDUH Series H-50.
Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. 2013. Report No.: HHS Publication No. (SMA) 13-4760, DAWN Series D-39.
Prescription Opioid Overdose Data [Internet]. 2016. Available at http://www.cdc.gov/drugoverdose/data/overdose.html. Accessed October 15, 2017.
Imtiaz S, Shield KD, Fischer B, et al.: Harms of prescription opioid use in the United States. Subst Abuse Treat Prev Policy. 2014; 9(43): 597X-9-43.
Paulozzi LJ, Ryan GW: Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006; 31(6): 506-511.
Bohnert AS, Ilgen MA, Trafton JA, et al.: Trends and regional variation in opioid overdose mortality among Veterans Health Administration patients, fiscal year 2001 to 2009. Clin J Pain. 2014; 30(7): 605-612.
Hall AJ, Logan JE, Toblin RL, et al.: Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008; 300(22): 2613-2620.
Bohnert AS, Valenstein M, Bair MJ, et al.: Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13): 1315-1321.
Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids [Internet]. Available at http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm. Accessed October 15, 2017.
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics [Internet]. 2017. Available at https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM515636.pdf. Accessed October 15, 2017.
Willy ME, Graham DJ, Racoosin JA, et al.: Candidate metrics for evaluating the impact of prescriber education on the safe use of extended-release/long-acting (ER/LA) opioid analgesics. Pain Med. 2014; 15(9): 1558-1568.
Robb MA, Racoosin JA, Sherman RE, et al.: The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf. 2012; 21(suppl 1): 9-11.
Platt R, Carnahan RM, Brown JS, et al.: The US Food and Drug Administration's Mini-Sentinel program: Status and direction. Pharmacoepidemiol Drug Saf. 2012; 21(suppl 1): 1-8.
Curtis LH, Weiner MG, Boudreau DM, et al.: Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012; 21(suppl 1): 23-31.
McGraw D, Rosati K, Evans B: A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf. 2012; 21: 18-22.
Products covered under the ER/LA Opioid Analgesics REMS Program [Internet]. Available at http://www.er-la-opioidrems.com/IwgUI/rems/products.action. Accessed October 15, 2017.
Foley KM: The treatment of cancer pain. N Engl J Med. 1985; 313(2): 84-95.
Salzman RT, Roberts MS, Wild J, et al.: Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage. 1999; 18(4): 271-279.
Opioid Morphine Equivalent Conversion Factors [Internet]. May 2014. Available at https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-March-2015.pdf. Accessed October 15, 2017.
Morasco BJ, Duckart JP, Carr TP, et al.: Clinical characteristics of veterans prescribed high doses of opioid medications for chronic non-cancer pain. Pain. 2010; 151(3): 625-632.
Starrels JL, Becker WC, Weiner MG, et al.: Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain. J Gen Intern Med. 2011; 26(9): 958-964.
Krebs EE, Ramsey DC, Miloshoff JM, et al.: Primary care monitoring of long-term opioid therapy among veterans with chronic pain. Pain Med. 2011; 12(5): 740-746.
Cicero TJ, Inciardi JA, Munoz A: Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005; 6(10): 662-672.
Nuckols TK, Anderson L, Popescu I, et al.: Opioid prescribing: A systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014; 160(1): 38-47.
Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016; 315(15): 1624-1645.
Summary Minutes of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting, May 3-4, 2016. Available at https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM509895.pdf. Accessed August 10, 2017.
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
